Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858853 | 0.85 | CASP1 (0.50) | KYNUSIRT2SIRT1SIRT3CTSK | |
| SCHEMBL4092001 | 0.84 | KYNU (0.54) | KYNUSIRT2SIRT1SIRT3CTSK | |
| SCHEMBL4090254 | 0.83 | KYNU (0.53) | KYNUSIRT2SIRT1SIRT3CTSK | |
| SCHEMBL16460413 | 0.81 | KYNU (0.50) | KYNUCTSKALDH1A1ALOX15F2 | |
| SCHEMBL4090590 | 0.81 | KYNU (0.53) | KYNUSIRT2SIRT1SIRT3CTSK | |
| SCHEMBL13858917 | 0.80 | MEN1 (0.51) | KYNUSIRT2SIRT1SIRT3ALDH1A1 | |
| SCHEMBL8239066 | 0.78 | KYNU (0.53) | KYNUSIRT2SIRT1SIRT3CTSK | |
| SCHEMBL13858793 | 0.78 | KYNU (0.41) | KYNUSIRT2SIRT1SIRT3ALDH1A1 | |
| SCHEMBL13858658 | 0.77 | MEN1 (0.43) | KYNUSIRT2SIRT1SIRT3ALDH1A1 | |
| SCHEMBL13858807 | 0.77 | GSTP1 (0.43) | KYNUSIRT2SIRT1SIRT3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212196-B2 | Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof | UNIVERSITE PARIS DESCARTES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140107078-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | UNIVWESITE D"AUVERGNE (FR) | 2014-04-17 | — | — | US | disclosed |
| WO-2012156931-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | UNIVERSITE PARIS DESCARTES (FR) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107078-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | HCAR3, HRH3, SSTR3 | KYNU 1692/4885SIRT2 2094/4885SIRT1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.